Pegcetacoplan

Therapeutic indications

Pegcetacoplan is indicated for:

Paroxysmal nocturnal haemoglobinuria (PNH)

Population group: only adults (18 years old or older)

Pegcetacoplan is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Pegcetacoplan is contraindicated in the following cases:

Infection caused by encapsulated bacteria

at least one of
Meningococcal infectious disease
Streptococcal pneumonia
Otitis media caused by Streptococcus pneumoniae
Sinusitis caused by Streptococcus pneumoniae
Haemophilus influenzae infection

Unvaccinated patients against Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae

at least one of
not Meningococcal vaccines
not Pneumococcal vaccines
not Haemophilus influenzae B, purified antigen conjugated

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: ASPAVELI Solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈